Tonghe Pharmaceutical (300636.SZ): Mirabegron and Empagliflozin have received GMP compliance certificates from the Australian Medicines and Therapeutics Administration.

Zhitong Finance APP reported that Tonghe Pharmaceutical (300636.SZ) announced that it recently received the GMP compliance certificates for Mirabegron and Empagliflozin issued by the Therapeutic Goods Administration (TGA) of Australia. Mirabegron is a selective 3-adrenergic receptor agonist that can enhance bladder capacity and storage ability by activating the 3-adrenergic receptors on the bladder detrusor, and is clinically used to treat symptoms of overactive bladder such as urgency urinary incontinence, urgency, and frequency. Empagliflozin is used for the treatment of type 2 diabetes.